Iroko Pharmaceuticals Signs New Strategic Agreement With Landsteiner Scientific To Bring ZORVOLEX® To Mexico

PHILADELPHIA--(BUSINESS WIRE)--Iroko Pharmaceuticals, LLC, a global specialty pharmaceutical company dedicated to advancing the science of analgesia, today announced that its affiliate, Iroko Pharmaceuticals Inc., signed a licensing agreement with Landsteiner Scientific, S.A. de C.V., for the exclusive rights to market and sell ZORVOLEX® (diclofenac) capsules in Mexico. Landsteiner Scientific will be responsible for obtaining regulatory and pricing approval, as well as the marketing and distribution of the medication.

“This additional licensing agreement with Landsteiner Scientific continues to expand potential access of ZORVOLEX to patients in Mexico, and marks Iroko’s third international agreement in the past four months,” said John Vavricka, President and CEO of Iroko Pharmaceuticals. “This is an important milestone for the company, as we look to increase our global commercialization footprint.”

Help employers find you! Check out all the jobs and post your resume.

Back to news